Drug name - Toviaz

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6858650 PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines
Jul, 2022

(3 months ago)

CN1390194A PFIZER Stable Salts Of New Derivatives Of 3, 3-Diphenyl Propylamine Compound
Nov, 2020

(1 year, 10 months ago)

CN1215045C PFIZER Stable Salts Of New Derivatives Of 3, 3-Diphenyl Propylamine Compound
Nov, 2020

(1 year, 10 months ago)

EP1230209A2 PFIZER Stable Salts Of Novel Derivatives Of 3,3-Diphenylpropylamines
Nov, 2020

(1 year, 10 months ago)

EP1690536A2 PFIZER Use Of R-(+)-2-(3-Diisopropylamino-1-Phenylpropyl)-4-Hydroxy-Methyl-Phenylisobutyric Acid Ester Hydrogenfumarate For The Treatment Of Urinary Incontinence And Other Spasmogenic Disorders
Nov, 2020

(1 year, 10 months ago)

EP1481964B1 PFIZER Stable Salts Of Novel Derivatives Of 3,3-Diphenylpropylamines
Nov, 2020

(1 year, 10 months ago)

EP1230209B1 PFIZER Stable Salts Of Novel Derivatives Of 3,3-Diphenylpropylamines
Nov, 2020

(1 year, 10 months ago)

EP1230209B3 PFIZER Stable Salts Of Novel Derivatives Of 3,3-Diphenylpropylamines
Nov, 2020

(1 year, 10 months ago)

EP1690536A3 PFIZER Use Of R-(+)-2-(3-Diisopropylamino-1-Phenylpropyl)-4-Hydroxy-Methyl-Phenylisobutyric Acid Ester Hydrogenfumarate For The Treatment Of Urinary Incontinence And Other Spasmogenic Disorders
Nov, 2020

(1 year, 10 months ago)

EP1690536B1 PFIZER Use Of R-(+)-2-(3-Diisopropylamino-1-Phenylpropyl)-4-Hydroxy-Methyl-Phenylisobutyric Acid Ester Hydrogenfumarate For The Treatment Of Urinary Incontinence And Other Spasmogenic Disorders
Nov, 2020

(1 year, 10 months ago)

EP1481964A1 PFIZER Stable Salts Of Novel Derivatives Of 3,3-Diphenylpropylamines
Nov, 2020

(1 year, 10 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6858650

(Pediatric)

PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines Jan, 2023

(2 months from now)

US8501723 PFIZER Pharmaceutical compositions comprising fesoterodine Jun, 2027

(4 years from now)

US8088398 PFIZER Pharmaceutical compositions comprising fesoterodine Jun, 2027

(4 years from now)

US7807715 PFIZER Pharmaceutical compositions comprising fesoterodine Jun, 2027

(4 years from now)

US7807715

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine Dec, 2027

(5 years from now)

US8088398

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine Dec, 2027

(5 years from now)

US8501723

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine Dec, 2027

(5 years from now)

Drugs and Companies using FESOTERODINE FUMARATE ingredient

Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
4MG TABLET, EXTENDED RELEASE;ORAL Prescription
8MG TABLET, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.